Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial

Cancer and Metastasis Reviews

Volumn 26, Issue 3-4, 2007, Pages 623-634

  Black, Peter C ^a   Dinney, Colin P N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; EGFR; IL 8; Metastasis; MMP 9; VEGF

Indexed keywords

ABX IL8; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GELATINASE B; GEMCITABINE; HALOFUGINONE; INTERLEUKIN 8; METHOTREXATE; PACLITAXEL; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VINBLASTINE;

ANGIOGENESIS; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; DRUG MECHANISM; GENE EXPRESSION; GENE TARGETING; HUMAN; LABORATORY TEST; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36148968401     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9084-9     Document Type: Review

References (116)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007). Cancer statistics, 2007. CA: a Cancer Journal for Clinicians, 57, 43-66.
2. Spiess, P. E., & Czerniak, B. (2006). Dual-track pathway of bladder carcinogenesis: Practical implications. Archives of Pathology & Laboratory Medicine, 130, 844-852.
3. Wu, X. R. (2005). Urothelial tumorigenesis: A tale of divergent pathways. Nature Reviews Cancer, 5, 713-725.
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005). Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European Urology, 48, 202-205; discussion 205-206.
5. Sonpavde, G., & Petrylak, D. P. (2006). Perioperative chemotherapy for bladder cancer. Critical Reviews in Oncology Hematology, 57, 133-144.
6. Fidler, I. J. (1990). Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Research, 50, 6130-6138.
7. Folkman, J. (1986). How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Research, 46, 467-473.
8. Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336.
9. Crew, J. P., O'Brien, T., Bradburn, M., Fuggle, S., Bicknell, R., Cranston, D., et al. (1997). Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Research, 57, 5281-5285.
10. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, R., Harris, A. L. (1995). Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Research, 55, 510-513.
11. Allen, L. E., & Maher, P. A. (1993). Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. Journal of Cellular Physiology, 155, 368-375.
12. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., & Folkman, J. (1993). Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. Journal of the National Cancer Institute, 85, 241-242.
13. Inoue, K., Slaton, J. W., Kim, S. J., Perrotte, P., Eve, B. Y., Bar-Eli, M., et al. (2000). Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Research, 60, 2290-2299.
14. Folkman, J. (1983). Angiogenesis: Initiation and modulation. Symposium on Fundamental Cancer Research, 36, 201-208.
15. Goddard, J. C., Sutton, C. D., Furness, P. N., O'Byrne, K. J., & Kockelbergh, R. C. (2003). Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clinical Cancer Research, 9, 2583-2586.
16. Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S. C., Skinner, D. G., et al. (1995). Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. Journal of the National Cancer Institute, 87, 1603-1612.
17. Canoglu, A., Gogus, C., Beduk, Y., Orhan, D., Tulunay, O., & Baltaci, S. (2004). Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. International Urology and Nephrology, 36, 401-405.
18. Dickinson, A. J., Fox, S. B., Persad, R. A., Hollyer, J., Sibley, G. N., & Harris, A. L. (1994). Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. British Journal of Urology, 74, 762-766.
19. Dinney, C. P., Babkowski, R. C., Antelo, M., Perrotte, P., Liebert, M., Zhang, H. Z., et al. (1998). Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. Journal of Urology, 160, 1285-1290.
20. Jaeger, T. M., Weidner, N., Chew, K., Moore, D. H., Kerschmann, R. L., Waldman, F. M., et al. (1995). Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. Journal of Urology, 154, 69-71.
21. Fidler, I. J. (1986). Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer and Metastasis Reviews, 5, 29-49.
22. Van Dyke, T., & Jacks, T. (2002). Cancer modeling in the modern era: progress and challenges. Cell, 108, 135-144.
23. Sabichi, A., Keyhani, A., Tanaka, N., Delacerda, J., Lee, I. L., Zou, C., et al. (2006). Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. Journal of Urology, 175, 1133-1137.
24. Sanchez-Carbayo, M., Socci, N. D., Charytonowicz, E., Lu, M., Prystowsky, M., Childs, G., et al. (2002). Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes. Cancer Research, 62, 6973-6980.
25. Lee, J. S., Chu, I. S., Mikaelyan, A., Calvisi, D. F., Heo, J., Reddy, J. K., et al. (2004). Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nature Genetics, 36, 1306-1311.
26. Tan, M. H., & Chu, T. M. (1985). Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour Biology, 6, 89-98.
27. Naito, S., von Eschenbach, A. C., Giavazzi, R., & Fidler, I. J. (1986). Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Research, 46, 4109-4115.
28. Shafie, S. M., & Liotta, L. A. (1980). Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Letters, 11, 81-87.
29. McLemore, T. L., Liu, M. C., Blacker, P. C., Gregg, M, Alley, M. C., Abbott, B. J., et al. (1987). Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Research, 47, 5132-5140.
30. Dinney, C. P., Fishbeck, R., Singh, R. K., Eve, B., Pathak, S., Brown, N., et al. (1995). Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. Journal of Urology, 154, 1532-1538.
31. Perrotte, P. J., Bielenberg, D. R., Eve, B. Y., & Dinney, C. P. (1997). Organ-specific angiogenesis and metastasis of human bladder carcinoma growing in athymic mice. Molecular Urology, 1, 299-307.
32. Tanaka, M., Gee, J. R., De La Cerda, J., Rosser, C. J., Zhou, J. H., Benedict, W. F., et al. (2003). Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. Journal of Urology, 170, 975-978.
33. Sweeney, P., Karashima, T., Ishikura, H., Wiehle, S., Yamashita, M., Benedict, W. F., et al. (2003). Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. Cancer Research, 63, 4017-4020.
34. Yamashita, M., Rosser, C. J., Zhou, J. H., Zhang, X. Q., Connor, R. J., Engler, H., et al. (2002). Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Therapy, 9, 687-691.
35. Zhou, J. H., Rosser, C. J., Tanaka, M., Yang, M., Baranov, E., Hoffman, R. M., et al. (2002). Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Therapy, 9, 681-686.
36. Watanabe, T., Shinohara, N., Sazawa, A., Harabayashi, T., Ogiso, Y., Koyanagi, T., et al. (2000). An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Therapy, 7, 1575-1580.
37. Hadaschik, B. A., Black, P. C., Sea, J. C., Metwalli, A. R., Fazli, L., Dinney, C. P., et al. (2007). A validated mouse model for orthotopic bladder cancer using transurethral tumor inoculation and bioluminescence imaging. BJU International (in press).
38. Okajima, E., Denda, A., Ozono, S., Takahama, M., Akai, H., Sasaki, Y., et al. (1998). Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Research, 58, 3028-3031.
39. Miyamoto, H., Yang, Z., Chen, Y. T., Ishiguro, H., Uemura, H., Kubota, Y., et al. (2007). Promotion of bladder cancer development and progression by androgen receptor signals. Journal of the National Cancer Institute, 99, 558-568.
40. Gunther, J. H., Jurczok, A., Wulf, T., Brandau, S., Deinert, I., Jocham, D., et al. (1999). Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Research, 59, 2834-2837.
41. Zhang, Z. T., Pak, J., Huang, H. Y., Shapiro, E., Sun, T. T., Pellicer, A., et al. (2001). Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene, 20, 1973-1980.
42. Zhang, Z. T., Pak, J., Shapiro, E., Sun, T. T., & Wu, X. R. (1999). Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Research, 59, 3512-3517.
43. Mitra, A. P., Datar, R. H., & Cote, R. J. (2006). Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. Journal of Clinical Oncology, 24, 5552-5564.
44. Bex, A., Vooijs, M., Horenblas, S., & Berns, A. (2002). Controlling gene expression in the urothelium using transgenic mice with inducible bladder specific Cre-lox recombination. Journal of Urology, 168, 2641-2644.
45. Talmadge, J. E., Singh, R. K., Fidler, I. J., & Raz, A. (2007). Murine models to evaluate novel and conventional therapeutic strategies for cancer. American Journal of Pathology, 170, 793-804.
46. Slaton, J. W., Millikan, R., Inoue, K., Karashima, T., Czerniak, B., Shen, Y., et al. (2004). Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. Journal of Urology, 171, 570-574.
47. Izawa, J. I., Slaton, J. W., Kedar, D., Karashima, T., Perrotte, P., Czerniak, B., et al. (2001). Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncology Reports, 8, 9-15.
48. Deryugina, E. I., & Quigley, J.P. (2006). Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews, 25, 9-34.
49. Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339, 58-61.
50. Blood, C. H., & Zetter, B. R. (1990). Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochimica et biophysica acta, 1032, 89-118.
51. Liotta, L. A., Thorgeirsson, U. P., & Garbisa, S. (1982). Role of collagenases in tumor cell invasion. Cancer and Metastasis Reviews, 1, 277-288.
52. Karelina, T. V., Goldberg, G. I., & Eisen, A. Z. (1995). Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors. Journal of Investigative Dermatology, 105, 411-417.
53. McCawley, L. J., & Matrisian, L. M. (2001). Matrix metalloproteinases: they're not just for matrix anymore! Current Opinion in Cell Biology, 13, 534-540.
54. Jodele, S., Blavier, L., Yoon, J. M., & DeClerck, Y. A. (2006). Modifying the soil to affect the seed: Role of stromal-derived matrix metalloproteinases in cancer progression. Cancer and Metastasis Reviews, 25, 35-43.
55. Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481-490.
56. Chaffer, C. L., Dopheide, B., McCulloch, D. R., Lee, A. B., Moseley, J. M., Thompson, E. W., et al. (2005). Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clinical and Experimental Metastasis, 22, 115-125.
57. Kawamata, H., Kameyama, S., Kawai, K., Tanaka, Y., Nan, L., Barch, D. H., et al. (1995). Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. International Journal of Cancer, 63, 568-575.
58. Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., & Itohara, S. (1998). Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Research, 58, 1048-1051.
59. Huang, S., Van Arsdall, M., Tedjarati, S., McCarty, M., Wu, W., Langley, R., et al. (2002). Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. Journal of the National Cancer Institute, 94, 1134-1142.
60. Acuff, H. B., Carter, K. J., Fingleton, B., Gorden, D. L., & Matrisian, L. M. (2006). Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Research, 66, 259-266.
61. Elkin, M., Reich, R., Nagler, A., Aingorn, E., Pines, M., de-Groot, N., et al. (1999). Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clinical Cancer Research, 5, 1982-1988.
62. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., et al. (1993). Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research, 53, 5365-5369.
63. Moses, M. A., Wiederschain, D., Loughlin, K. R., Zurakowski, D., Lamb, C. C., & Freeman, M. R. (1998). Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Research, 58, 1395-1399.
64. Bianco, F. J., Jr., Gervasi, D. C., Tiguert, R., Grignon, D. J., Pontes, J. E., Crissman, J. D., et al. (1998). Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clinical Cancer Research, 4, 3011-3016.
65. Sier, C. F., Casetta, G., Verheijen, J. H., Tizzani, A., Agape, V., Kos, J., et al. (2000). Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: A comparison with clinically used tumor markers. Clinical Cancer Research, 6, 2333-2340.
66. Gerhards, S., Jung, K., Koenig, F., Daniltchenko, D., Hauptmann, S., Schnorr, D., et al. (2001). Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology, 57, 675-679.
67. Kawamura, K., Kamiya, N., Suyama, T., Shimbo, M., Oosumi, N., Suzuki, H., et al. (2004). In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer. Journal of Urology, 172, 1480-1484.
68. Grignon, D. J., Sakr, W., Toth, M., Ravery, V., Angulo, J., Shamsa, F., et al. (1996). High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Research, 56, 1654-1659.
69. Kader, A. K., Liu, J., Shao, L., Dinney, C. P., Lin, J., Wang, Y., et al. (2007). Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clinical Cancer Research, 13, 2614-2620.
70. Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science, 295, 2387-2392.
71. Matsushima, K., Morishita, K., Yoshimura, T., Lavu, S., Kobayashi, Y., Lew, W., et al. (1988). Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. Journal of Experimental Medicine, 167, 1883-1893.
72. Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., et al. (1992). Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258, 1798-1801.
73. Luca, M., Huang, S., Gershenwald, J. E., Singh, R. K., Reich, R., & Bar-Eli, M. (1997). Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. American Journal of Pathology, 151, 1105-1113.
74. Brew, R., Erikson, J. S., West, D. C., Kinsella, A. R., Slavin, J., & Christmas, S. E. (2000). Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine, 12, 78-85.
75. Yoshida, S., Ono, M., Shono, T., Izumi, H., Ishibashi, T., Suzuki, H., et al. (1997). Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Molecular and Cellular Biology, 17, 4015-4023.
76. Inoue, K., Wood, C. G., Slaton, J. W., Karashima, T., Sweeney, P., & Dinney, C. P. (2001). Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncology Reports, 8, 955-964.
77. Yuan, A., Chen, J. J., Yao, P. L., & Yang, P. C. (2005). The role of interleukin-8 in cancer cells and microenvironment interaction. Frontiers in Bioscience, 10, 853-865.
78. Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X. D., et al. (2002). Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. American Journal of Pathology, 161, 125-134.
79. Inoue, K., Slaton, J. W., Eve, B. Y., Kim, S. J., Perrotte, P., Balbay, M. D., et al. (2000). Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clinical Cancer Research, 6, 2104-2119.
80. Mian, BM, Dinney, CP, Bermejo, CE, Sweeney, P, Tellez, C, Yang, XD et al. (2003). Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clinical Cancer Research, 9, 3167-3175.
81. Yang, C. C., Chu, K. C., & Yeh, W. M. (2004). The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urologic Oncology, 22, 1-6.
82. Bernardini, S., Fauconnet, S., Chabannes, E., Henry, P. C., Adessi, G., & Bittard, H. (2001). Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. Journal of Urology, 166, 1275-1279.
83. Wu, W., Shu, X., Hovsepyan, H., Mosteller, R. D., & Broek, D. (2003). VEGF receptor expression and signaling in human bladder tumors. Oncogene, 22, 3361-3370.
84. Xia, G., Kumar, S. R., Hawes, D., Cai, J., Hassanieh, L., Groshen, S., et al. (2006). Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. Journal of Urology, 175, 1245-1252.
85. Inoue, K., Slaton, J. W., Davis, D. W., Hicklin, D. J., McConkey, D. J., Karashima, T., et al. (2000). Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clinical Cancer Research, 6, 2635-2643.
86. Davis, D. W., Inoue, K., Dinney, C. P., Hicklin, D. J., Abbruzzese, J. L., & McConkey, D. J. (2004). Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Research, 64, 4601-4610.
87. Posey, J. A., Ng, T. C., Yang, B., Khazaeli, M. B., Carpenter, M. D., Fox, F., et al. (2003). A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clinical Cancer Research, 9, 1323-1332.
88. Mohamedali, K. A., Kedar, D., Sweeney, P., Kamat, A., Davis, D. W., Eve, B. Y., et al. (2005). The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia, 7, 912-920.
89. Mohamedali, K. A., Poblenz, A. T., Sikes, C. R., Navone, N. M., Thorpe, P. E., & Darnay, B. G. (2006). Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Research, 66, 10919-10928.
90. Ran, S., Mohamedali, K. A., Luster, T. A., Thorpe, P. E., & Rosenblum, M. G. (2005). The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia, 7, 486-496.
91. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335-2342.
92. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., et al. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New England Journal of Medicine, 349, 427-434.
93. Sawhney, R., Bourgeois, D., & Chaudhary, U. B. (2006). Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: A look ahead. Annals of Oncology, 17, 1360-1369.
94. Kassouf, W., Dinney, C. P., Brown, G., McConkey, D. J., Diehl, A. J., Bar-Eli, M., et al. (2005). Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Research, 65, 10524-10535.
95. Chow, N. H., Liu, H. S., Lee, E. I., Chang, C. J., Chan, S. H., Cheng, H. L., et al. (1997). Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Research, 17, 1293-1296.
96. Sriplakich, S., Jahnson, S., & Karlsson, M. G. (1999). Epidermal growth factor receptor expression: Predictive value for the outcome after cystectomy for bladder cancer? British Journal of Urology International International, 83, 498-503.
97. Mellon, K., Wright, C., Kelly, P., Horne, C. H., & Neal, D. E. (1995). Long-term outcome related to epidermal growth factor receptor status in bladder cancer. Journal of Urology, 153, 919-925.
98. Bue, P., Wester, K., Sjostrom, A., Holmberg, A., Nilsson, S., Carlsson, J., et al. (1998). Expression of epidermal growth factor receptor in urinary bladder cancer metastases. International Journal of Cancer, 76, 189-193.
99. Cheng, J., Huang, H., Zhang, Z. T., Shapiro, E., Pellicer, A., Sun, T. T., et al. (2002). Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Research, 62, 4157-4163.
100. Shrader, M., Pino, M. S., Brown, G., Black, P., Adam, L., Bar-Eli, M., et al. (2007). Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Molecular Cancer Therapeutics, 6, 277-285.
101. Kassouf, W., Luongo, T., Brown, G., Adam, L., & Dinney, C. P. (2006). Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. Journal of Urology, 176, 787-792.
102. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., et al. (1999). Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research, 5, 257-265.
103. Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., et al. (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology, 151, 1523-1530.
104. Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., et al. (2000). Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clinical Cancer Research, 6, 4874-4884.
105. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129-2139.
106. Blehm, K. N., Spiess, P. E., Bondaruk, J. E., Dujka, M. E., Villares, G. J., Zhao, Y. J., et al. (2006). Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy. Clinical Cancer Research, 12, 4671-4677.
107. Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-1537.
108. Esrig, D., Spruck, C. H., 3rd, Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., et al. (1993). p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. American Journal of Pathology, 143, 1389-1397.
109. Bochner, B. H., Esrig, D., Groshen, S., Dickinson, M., Weidner, N., Nichols, P. W., et al. (1997). Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Clinical Cancer Research, 3, 1615-1622.
110. Malats, N., Bustos, A., Nascimento, C. M., Fernandez, F., Rivas, M., Puente, D., et al. (2005). P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncology, 6, 678-686.
111. Imao, T., Koshida, K., Endo, Y., Uchibayashi, T., Sasaki, T., & Namiki, M. (1999). Dominant role of E-cadherin in the progression of bladder cancer. Journal of Urology, 161, 692-698.
112. Inoue, K., Slaton, J. W., Karashima, T., Yoshikawa, C., Shuin, T., Sweeney, P., & et al. (2000). The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clinical Cancer Research, 6, 4866-4873.
113. Wakatsuki, S., Watanabe, R., Saito, K., Saito, T., Katagiri, A., Sato, S., et al. (1996). Loss of human E-cadherin (ECD) correlated with invasiveness of transitional cell cancer in the renal pelvis, ureter and urinary bladder. Cancer Letters, 103, 11-17.
114. Syrigos, K. N., Krausz, T., Waxman, J., Pandha, H., Rowlinson-Busza, G., Verne, J., et al. (1995). E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. International Journal of Cancer, 64, 367-370.
115. Kim, J. H., Tuziak, T., Hu, L., Wang, Z., Bondaruk, J., Kim, M., et al. (2005). Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Laboratory Investigation, 85, 532-549.
116. Havaleshko, D. M., Cho, H., Conaway, M., Owens, C. R., Hampton, G., Lee, J. K., et al. (2007). Prediction of drug combination chemosensitivity in human bladder cancer. Molecular Cancer Therapeutics, 6, 578-586.